Published in Arch Neurol on January 01, 2006
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain (2008) 1.34
A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Syst Biol (2008) 1.14
Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol (2011) 1.12
Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol (2008) 1.03
Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt (2011) 0.99
Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients. Mult Scler (2010) 0.91
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci (2011) 0.90
Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis. Glycobiology (2015) 0.84
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice. PLoS One (2012) 0.81
Multiple sclerosis therapy: an update on recently finished trials. J Neurol (2007) 0.78
Stem cell therapy for central nerve system injuries: glial cells hold the key. Neural Regen Res (2014) 0.77
A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases. Mol Cell Proteomics (2011) 0.77
Neural stem cells respond to stress hormones: distinguishing beneficial from detrimental stress. Front Physiol (2015) 0.76
Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. Stem Cells Transl Med (2015) 0.76
Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosis. Nat Rev Neurol (2010) 0.76
Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis. J Neuroimmunol (2015) 0.76
Radiopharmaceutical stem cell tracking for neurological diseases. Biomed Res Int (2014) 0.76
Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. J Neurol (2016) 0.75
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A (2004) 4.70
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol (2007) 3.39
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. J Comp Neurol (2004) 3.20
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Acute disseminated encephalomyelitis. Neurology (2007) 2.84
CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol (2003) 2.79
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler (2013) 2.20
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity (2012) 2.18
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med (2012) 2.11
Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nat Genet (2003) 1.96
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med (2007) 1.93
Body size and risk of MS in two cohorts of US women. Neurology (2009) 1.89
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol (2011) 1.85
Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology (2009) 1.80
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest (2003) 1.76
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70
Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain (2008) 1.67
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2013) 1.51
Pediatric multiple sclerosis. Nat Rev Neurol (2009) 1.50
Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol (2009) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology (2013) 1.46
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
TGF-beta induces IL-9 production from human Th17 cells. J Immunol (2010) 1.40
Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol (2007) 1.39
The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler (2014) 1.36
Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther (2005) 1.36
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain (2008) 1.34
Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci (2006) 1.31
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med (2012) 1.29
Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol (2006) 1.26
Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity (2012) 1.24
Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging (2011) 1.24
JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.23
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol (2013) 1.15
Smoking and disease progression in multiple sclerosis. Arch Neurol (2009) 1.13
Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol (2011) 1.12
CD4+ T cells regulate surgical and postinfectious adhesion formation. J Exp Med (2002) 1.11
Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol (2010) 1.09
Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol (2004) 1.09
Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis. Ann Neurol (2008) 1.08
Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol (2011) 1.07
Modeling disease severity in multiple sclerosis using electronic health records. PLoS One (2013) 1.06
Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. J Immunol (2011) 1.06
Immunopathogenesis of multiple sclerosis. Clin Immunol (2011) 1.05
IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol (2002) 1.05
Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol (2010) 1.04
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol (2009) 1.04
Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol (2008) 1.03
Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. Physiol Genomics (2003) 1.02
Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt (2011) 0.99
The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging (2011) 0.98
Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health (2012) 0.97
Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol (2012) 0.95
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport (2014) 0.95
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol (2008) 0.93
Stem cells: cross-talk and developmental programs. Philos Trans R Soc Lond B Biol Sci (2004) 0.93
Sexual disparities in the incidence and course of MS. Clin Immunol (2013) 0.92
CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci (2010) 0.92
Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry (2011) 0.92
The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res (2012) 0.91
Effect of gender on late-onset multiple sclerosis. Mult Scler (2012) 0.90
Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int (2013) 0.90
Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol (2005) 0.89
Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res (2003) 0.88
Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int (2011) 0.88
Pathogenesis of pediatric multiple sclerosis. J Child Neurol (2012) 0.88
Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol (2002) 0.88
Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol (2009) 0.88
Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol (2003) 0.87
A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One (2010) 0.87